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Abstract Retroviral vectors pDOL/NeuN and pDOL/NeuT were used to express normal and transforming rat neu cDNAs in PCI2 cells. DOL/ 
NeuT-infected cells exhibited a high frequency of spontaneous neurite outgrowth while DOL/NeuN-infected cells showed neurite outgrowth in the 
presence of heregulin, a putative ligand for the neu receptor tyrosine kinase. In both cases, neurite outgrowth was preceded by phosphorylation f
p185 ncu and several other cellular proteins. Thus the neu tyrosine kinase can elicit morphological nd biochemical changes resembling, but distinct 
from, those stimulated by NGF, and heregulin stimulates neu to elicit these effects in PCI2 cells. 
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1. Introduction 
The human c-erbB2 tyrosine kinase and its rat homolog, neu, 
together with erbB3 [1] and erbB4 [2], are members of a family 
of transmembrane r ceptor tyrosine kinases for which the epi- 
dermal growth factor (EGF) receptor is the prototype [3]. As 
gene amplification and overexpression f each of these has been 
associated with various cancers, there is considerable interest 
in identifying their respective ligands and further understanding 
the mechanisms by which these receptors are activated. Re- 
cently, a family of peptides related to EGF  have been identified 
as possible candidates for the neu/erbB2 ligand. The first of  
these was heregulin, a factor purified from medium conditioned 
by human mammary carcinoma cells [4], and its rat homolog, 
the neu differentiation factor (NDF)  [5]. More recently, ace- 
tylcholine receptor-inducing activity (ARIA) [6], and glial 
growth factor [7] were discovered and found to be members of 
the heregulin family. The tissue distribution of these factors 
suggests that neu/erbB2 may not only be involved in regulating 
the growth and survival of mammary epithelial cells, but also 
may play a previously unappreciated role in the development 
and differentiation of the nervous ystem. It was also somewhat 
surprising to find that while each of these factors will promote 
autophosphorylation f neu/erbB2 protein in certain cells, not 
all cells that express neu/erbB2 bind or respond [8]. These 
findings call into question the role of neu/erbB2 in heregulin 
signalling. Recent studies in fact suggest hat the erbB3 [9,10] 
or erbB4 proteins are necessary for heregulin-responsiveness. 
In order to further examine the possible participation of  
neu/erbB2 and its putative ligand heregulin  neuronal activi- 
ties, we have used the well established model for neuronal 
differentiation, the rat pheochromocytoma (PC 12) cell line. We 
felt it was of  interest o address two important questions re- 
garding neu/erbB2 function. The first was whether the activated 
(transforming) neu tyrosine kinase was capable of eliciting 
neurite extension in a manner similar to the NGF-st imulated 
trk proto-oncogene product [11-14] or if neu/erbB2 behaved in 
a manner more similar to another member of  the subclass 1 
receptor tyrosine kinases, the EGF  receptor. I f  the former were 
true, we then were interested in determining if PC12 cells ex- 
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pressing normal neu were capable of responding to heregulin 
and yielding a phenotype similar to that elicited by transform- 
ing neu. 
2. Materials and methods 
2.1. Materials 
NGF (2.5S) was purchased from Boehringer-Mannheim (Indianapo- 
lis, IN). Anti-phosphotyrosine antibody was purified from the culture 
medium of FB2 hybridoma cells, obtained from ATCC. Anti-neu anti- 
bodies were either a rabbit polyclonal provided by Dr. Randy 
Schatzman, Syntax Co., Palo Alto, CA or anti c-neu Ab-3 from Onco- 
gene Science (Uniondale, NY). The plasmids pDOL/NeuN and pDOL/ 
NeuT were kindly provided by Dr. David Stern, Yale Medical School. 
Recombinant heregulin (rHRG-fl1177_241) was provided by Dr. Mark 
Sliwkowski, Genentech, Inc. 
2.2. Cell culture 
PA317 retrovirus packaging cells [16] were grown in Dulbecco's 
Modified Eagles' Medium (DMEM) supplemented with 10% fetal bo- 
vine serum. PCI2 cells were propagated on tissue culture plastic in 
DMEM supplemented with 10% heat-inactivated horse serum and 5% 
fetal bovine serum. Where indicated, neurite outgrowth was tested in 
dishes that had been coated with collagen (rat tail, Type 1) according 
to the supplier's (Sigma) recommended protocol. 
2.3. Retrovirus-mediated transfer of N uN and NeuT genes 
Plasmids pDOL/NeuN and pDOL/NeuT [17] were transfected into 
PA317 retrovirus packaging cells [16] by the calcium-phosphate tech- 
nique [18]. Stable-transfected packaging cells were selected in 500 ltg/ml 
(active) antibiotic G418 (Geneticin, GIBCO). PC12 cells were seeded 
at 1 x 106 per 60 mm dish one day prior to infection. Virus stocks 
consisted of media harvested from the packaging cells, filtered through 
0.4 micron filters, and supplemented with heat-inactivated horse serum 
(5%) and polybrene (6/lg/ml). Infections were carried out by incubating 
PC12 cells in virus stocks for 24 h. Cells from each 60 mm plate were 
then split onto three 100 mm dishes and maintained without passage 
for 3 to 5 weeks in medium containing G418 (400/~g/ml, active). 
2.4. Immunoprecipitation a d Western blot analysis 
On the day prior to immunoprecipitation, the cell medium was 
changed to DMEM plus 0.5% FBS with or without 1 /IM sodium 
orthovanadate. Where indicated, growth factors or TPA were added 
directly to the medium for a 5-min incubation. Cells were then washed 
in cold Tris-buffered saline (TBS) and suspended in lysis buffer consist- 
ing of TBS plus 1% NP-40, 10% glycerol, 1 mM phenyl-methylsulfon- 
ylfluoride, 1/tg/ml eupeptin, 1 mM EGTA, 40 mM sodium fluoride, 
100/.tM ammonium olybdate, and 1 mM sodium orthovanadate. The 
lysates were incubated 15 min on ice after which insoluble materials 
were pelleted in a microfuge (10 min). Each supernate was then incu- 
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bated for 2 h on ice with 30/tl of 50% suspension of protein A- 
Sepharose which had been preincubated with anti-phosphotyrosine an- 
tibody. The immune complexes were pelleted, boiledin 40/11 sample 
buffer, fractionated by SDS-PAGE (8% acrylamide) and transferred to 
nitrocellulose. The blots were blocked in 3% BSA in TBS plus 0.05% 
Tween 20 for 1 h at room temperature and incubated overnight in 
antibody (either anti-PY of anti-neu). Bound antibody was detected 
using [~zSI]protein A (NEN). 
3. Results 
3.1. Infection of PC12 cells with DOL/NeuN and DOL/NeuT 
viruses 
Retroviral infection of PC12 cells followed by selection in 
G418, yielded discrete, clonal, clusters of cells. These clones 
could be classified into three groups based on the morphology 
of their cells (Fig. 1). One type consisted of tightly packed, 
undifferentiated cells (Fig. 1A). A second type was similar to 
the first except hat cells with neurite-like processes were seen 
at the periphery (Fig. 1B). The third type consisted of dispersed 
cells of which the majority displayed long neuritic processes 
(Fig. 1C). Clones of cells infected with the DOL/NeuN (encod- 
ing the normal neu tyrosine kinase) virus or with control con- 
structs were indistinguishable from one another and generally 
appeared undifferentiated; neurite xtension was rare (Fig. 1 D, 
and data not shown). In contrast, cells in the majority of pri- 
mary clones infected with DOL/NeuT virus (encoding the 
transforming neu protein) had neurites. These results suggested 
that transforming neu promoted ifferentiation of PC12 cells. 
Because of the variability noted among PC12 cells with differ- 
ent passage histories, we performed several infections of PC12 
cells obtained from another laboratory, (Dr. M. Chao, Cornell 
Medical School). Again, cells infected with ZIP or DOL control 
vectors were indistinguishable from uninfected cells, whereas 
infection with DOL/NeuT virus consistently yielded popula- 
tions of cells which displayed a high frequency of spontaneous 
neurite outgrowth (Fig. 2A). 
3.2. Response of DOL/NeuN- and DOL/NeuT-infected cells to 
NGF,, dbcAMP, TPA, and sodium orthovanadate 
We found no evidence that infection with DOL/NeuN, DOL/ 
NeuT, or control viruses consistently altered neurite outgrowth 
or cell growth rate in the presence of NGF at concentrations 
ranging from 0.1 to 100 ng/ml (not shown). Dibutyryl-cycli- 
cAMP (dbcAMP) at a low concentration (40 pM) caused very 
little outgrowth in control or DOL/NeuN-infected populations 
but caused a substantial increase in the number of neurite- 
bearing DOL/NeuT-infected cells (Fig. 2B). Higher concentra- 
tions (0.2 mM) of dbcAMP caused significant neurite out- 
growth (20-50%) in uninfected, vector-infected, and DOL/ 
NeuN-infected cells, and almost complete (i.e. greater than 
80%) neurite xtension in DOL/NeuT-infected cells. After elab- 
orating neurites in the presence of dbcAMP, many DOL/NeuT- 
infected cells remained viable and retained their neurites for up 
to two weeks in the absence of serum or NGF. Uninfected, 
ZIP-infected, DOL/NeuN-infected, and undifferentiated DOL/ 
NeuT-infected PC12 all died in these conditions (not shown). 
Incubation with the protein kinase C-activating phorbol 
ester, TPA, did not promote neurite outgrowth in uninfected 
PC 12 cells or control vector-infected cells, but did elicit a small, 
but reproducible, increase in the number of neurite-bearing 
cells in populations of both DOL/NeuN- and DOL/NeuT-in- 
fected cells (Fig. 2C). 
While testing conditions for the study of tyrosine phospho- 
rylation, we observed that PC12 cells incubated with subtoxic 
levels of sodium orthovanadate ( -  5/tM) tended to display 
neurite-like processes. With uninfected, vector-infected, and 
DOL/NeuN virus-infected PC12 cells, these processes were 
generally too short to be counted as neurites (arbitrarily defined 
A. B. 
C. D. Number of Clones (~) 
DDOL/Ne~N DDOL/NeuT DZIDGDA 
A. 25 (67.6) 2 (5 .6)  26 (70.3) 
B. I 1 (29.7) 14 (38.9) I0 (27.0) 
C. 1 (2.7)  20 (556)  I (27)  
Fig. 1. Morphologies of cells in clones after 3 weeks of selection in G418. The cells were categorized as (A) Undifferentiated, (B) Intermediate or 
mixed, in which typical colonies appeared as a tight cluster of undifferentiated cells with a few ceils at the edge showing neurite-like processes or 
(C) neurite-bearing. (D) Table showing the number and percentage of clones fitting categories A,B,C typically appearing after infection with Neu+ 
retroviruses or a control pZIP-based viral construct arrying an unexpressible, unrelated gene. 
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Fig. 2. Spontaneous and induced neurite outgrowth in infected and uninfected PC12 cells. Cells were plated and allowed to settle overnight in DMEM 
supplemented with 10% FBS and 5% horse serum. Media were then (day 0)exchanged for DMEM with 1% FBS and 0.5% HS with or without (control) 
dbcAMP, sodium orthovanadate, or TPA. Neurites were scored in three randomly selected fields in a phase contrast microscope. The values represent 
the weighted mean + S.E. (A) Neurites scored at day 2 in control medium. Shown are the parental PC12 line, two lines independently infected with 
control vector ZIP, one line infected with DOL/NeuN (designated 171.2), and three lines independently infected wi h DOL/NeuT (171.1,172.1 and 
176). (B) Neurites scored at day 2 of incubation i  the presence or absence of dbcAMP. (C) Neurites scored at day 1 of incubation i  the presence 
or absence of 20 nM TPA. (D) Neurites scored at day 1 of incubation in the presence or absence of sodium orthovanadate. 
as processes longer than two cell body diameters). In contrast, 
incubation of DOL/NeuT-infected cells with sodium orthova- 
nadate resulted in a dramatic increase in the percentage ofcells 
bearing neurites (Fig. 2D). 
3.3. The effect of heregulin 
The percentage of PC12 or vector control cells bearing 
neurites was not significantly altered uring a three day incuba- 
tion with recombinant heregulinfll (HRG), at levels up to 10 
nM (Fig. 3). DOL/NeuT-infected PC12 cells also showed no 
morphological changes in response to HRG alone (data not 
shown). However, neurite outgrowth was observed in DOL/ 
NeuN-infected PC12 cells incubated with HRG at concentra- 
tions of 1 nM and lower (Fig. 3 and data not shown). When 
heregulin was added together with 2 nM TPA, neurite xten- 
sion was increased in PC12 cells expressing either normal neu 
or the transforming neu protein (Fig. 3). 
3.4. Protein tyrosine phosphorylation 
Anti-phosphotyrosine immunoprecipitates from DOL/ 
NeuT-infected cells contained neu (Mr ~ 185 kDa), the phospho- 
rylation of which was enhanced uring incubation in sodium 
orthovanadate (Fig. 4, compare lanes 3 and 4). Similarly, treat- 
ment of DOL/NeuN-infected cells with heregulin resulted in the 
rapid phosphorylation of neu (Fig. 4, compare lanes 1 and 2). 
We also found that heregulin stimulated the phosphorylation 
of the same group of proteins that were detected in cells ex- 
pressing the transforming neu protein (data not shown). The 
major proteins in anti-phosphotyrosine immunoprecipitates of 
orthovanadate-treated, DOL/NeuT-infected cells or heregulin- 
treated, DOL/NeuN-infected cells (e.g. M r ~ 125 kDa, 95 kDa, 
75 kDa, and 70 kDa) comigrated with a subset of proteins that 
are phosphorylated after treatment with NGF or EGF (data 
not shown). 
4. Discussion 
The biochemical events following the activation of different 
receptor tyrosine kinases are highly regulated and specific in 
PCI2 cells, as evidenced by the differing effects of EGF and 
NGF. In the present study, we find that the expression of the 
transforming neu protein in PC12 cells elicits a high frequency 
of spontaneous neurite outgrowth and an enhanced responsive- 
ness to agents that are known to act synergistically with NGF. 
Expression of the normal neu tyrosine kinase in PC12 cells 
correlated with an acquired responsiveness to heregulin and an 
increased tendency to form neurites in the presence of the 
protein kinase C-activator, TPA. In these respects, DOLl 
NeuT- and heregulin-stimulated DOL/NeuN-infected cells be- 
haved like cells receiving NGF. Thus, the actions of neu/erbB2 
and the EGF receptor are distinct in both oncogenically-acti- 
vated and growth factor-stimulated context in PC12 cells. 
Neurite extension from the DOL/NeuT-infected cells was 
enhanced when the cells were incubated with sodium orthova- 
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nadate, an inhibitor of tyrosine phosphatases. This was accom- 
panied by the apparent autophosphorylation of neu and the 
elevated phosphorylation of several cellular proteins. These 
results uggest that the tyrosine kinase activity is constitutively 
higher in DOL/NeuT-infected cells, compared to control cells, 
and are consistent with the proposal that the activated neu 
tyrosine kinase is responsible, ither directly or indirectly, for 
eliciting neurite outgrowth. 
Some differences were observed in the characteristics of the 
biological responses elicited by activated neu and trk. For ex- 
ample, neither the NeuT- nor the NeuN-containing cells 
showed an enhanced sensitivity to NGF. Thus, the neu tyrosine 
kinase did not appear to be capable of 'priming' cells as occurs 
upon the prior exposure of PC12 cells to NGF or upon the 
expression of the v-src tyrosine kinase [19]. PC 12 cells express- 
ing NeuT also did not show any changes in their responsiveness 
to EGF, whereas NGF normally causes EGF receptor down- 
regulation [20]. An additional difference is that our lines of 
DOL/NeuT-infected PC12 cells have continued to proliferate 
at normal rates, while the addition of NGF to PC12 cells, as 
well as the expression of the v-src and ras oncogenes, cause 
these cells to stop proliferating [19,21,22]. The latter findings 
with NeuT may be related to the fact that this oncogene was 
first identified in cells that both proliferate and extend neurites, 
and it might not be expected that transforming (activated) neu 
would cause PC 12 ceils to withdrawal from the cell cycle. Taken 
together, these results suggest that while the NGF receptor/trk 
oncogene product and the neu/erbB-2 tyrosine kinase both 
elicit neurite xtension i PC12 cells, they do not share identical 
signaling pathways in these cells. 
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Fig. 3. Heregulin and TPA-stimulated neurite outgrowth in control and 
DOL/NeuN-infected PC12 cells. Plating and conditions were as de- 
scribed in Fig. 2. Neurites were scored at day 3 after addition of 
heregulin and/or TPA. 
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Fig. 4. Tyrosine phosphorylation in control and DOL/Neu-infected 
PC 12 cells. Lanes 1 and 2: DOL/NeuN-infected cells (177.2) were incu- 
bated 18 h in DMEM with 0.5% FBS and 1 pM sodium orthovanadate 
followed by no further treatment (lane 1) or a 5 min incubation n 10 
nM heregulin (lane 2).Lanes 3 and 4: DOL/NeuT-infected cells (I71.1) 
were incubated 18 h in DMEM with 0.5% FBS without (lane 3) or with 
(lane 4) 1 pM sodium orthovanadate. Lane 5 shows p185 he" im- 
munoprecipitated from an overexpressing fibroblast line, DHFR/G8 
[23]. 
The proposal that p185neu/erbB2 is the receptor for hereg- 
ulin was based on the observation that this factor binds with 
high affinity to breast carcinoma cells that overexpress neu/ 
erbB-2, and that this binding stimulates phosphorylation f a 
protein identified as p185neu/erbB2. However, it has been pro- 
posed that unidentified cell-specific factors are required in con- 
junction with neu/erbB2 to form a functional heregulin receptor 
[2,9] or that perhaps neu/erbB2 is not the receptor at ll. The 
present studies support a role for neu/erbB2 in mediating a
heregulin response in PC 12 cells. Apparently PC 12 cells express 
all the components required for responsiveness to heregulin 
and these become fully functional upon the introduction of 
NeuN. Sliwkowski et al., have proposed that the erbB3 and 
neu/erbB2 proteins can act together to c nfer heregulin respon- 
siveness in some cells [10] and a similar suggestion has been 
made for erbB4 and neu/erbB2 [24]. We are currently examin- 
ing our PC12 cells for expression of the erbB3 and erbB4 gene 
products as a first step toward determining the possible involve- 
ment of one of these proteins in the actions of heregulin and 
neu/erbB2. 
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